F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 0.82 EUR 1.23%
Market Cap: €303.7m

Fluidigm Corp
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Fluidigm Corp
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Total Equity
$424.3m
CAGR 3-Years
23%
CAGR 5-Years
25%
CAGR 10-Years
14%
Thermo Fisher Scientific Inc
NYSE:TMO
Total Equity
$53.4B
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Total Equity
$52.5B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
8%
Waters Corp
NYSE:WAT
Total Equity
$2.6B
CAGR 3-Years
72%
CAGR 5-Years
62%
CAGR 10-Years
2%
Agilent Technologies Inc
NYSE:A
Total Equity
$6.9B
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
5%
IQVIA Holdings Inc
NYSE:IQV
Total Equity
$6.5B
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Fluidigm Corp
Glance View

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
0.52 EUR
Overvaluation 36%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Total Equity?
Total Equity
424.3m USD

Based on the financial report for Dec 31, 2025, Fluidigm Corp's Total Equity amounts to 424.3m USD.

What is Fluidigm Corp's Total Equity growth rate?
Total Equity CAGR 10Y
14%

Over the last year, the Total Equity growth was -10%. The average annual Total Equity growth rates for Fluidigm Corp have been 23% over the past three years , 25% over the past five years , and 14% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett